Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs

• Published in: Cancers Vol. 16; no. 19; p. 3330
• Main Authors: Guerrero-Ramos, Félix, González-Padilla, Daniel Antonio, Pérez-Cadavid, Santiago, García-Rojo, Esther, Tejido-Sánchez, Ángel, Hernández-Arroyo, Mario, Gómez-Cañizo, Carmen, Rodríguez-Antolín, Alfredo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.09.2024; MDPI
• Subjects: Age; Bladder cancer; Cancer therapies; Care and treatment; Chemotherapy; Comorbidity; Complications and side effects; Disease; Electronic health records; Emergency medical care; Hematuria; Invasiveness; Life expectancy; Lymphatic system; Medical prognosis; Metastases; Metastasis; Palliation; Palliative care; Palliative treatment; Patient outcomes; Patients; Population; Population studies; Prognosis; Radiation therapy; Survival; Urological surgery; Variables; Spain; prognosis; bladder cancer; supportive care; survival
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16193330

To assess the survival outcomes of patients diagnosed with muscle-invasive bladder cancer (MIBC) who are not candidates for curative treatment and to identify the factors influencing these outcomes. We conducted an analysis of patients diagnosed with MIBC who were either unable or unwilling to undergo curative therapy. We evaluated overall survival (OS) and cancer-specific survival (CSS) and examined their associations with various clinical variables. Additionally, we assessed emergency department visits and palliative procedures. The study included 142 patients with a median age of 79.4 years and a Charlson Comorbidity Index of 9.8. At diagnosis, 59.2% of the patients had localized disease, 23.2% had metastatic disease, and 49.3% presented with hydronephrosis. Curative treatment was excluded due to comorbidities in 40.1% of cases and advanced disease stage in 36.6%. The 1-year and 2-year OS rates were 42.8% and 23.6%, respectively, with a median survival of 10.6 months. The 1-year and 2-year CSS rates were 49.6% and 30.2%, respectively, with a median survival of 11.9 months. Worse survival outcomes were associated with advanced disease stage and the presence of hydronephrosis. Patients excluded from curative treatment solely due to age had a relatively better prognosis. On average, patients visited the emergency department three times: 19% underwent palliative transurethral resection of the bladder tumor, 14.8% received radiotherapy to control hematuria, and nephrostomy tubes were placed in 26.1% of cases. Patients with MIBC who are unable or unwilling to undergo curative treatment have a median overall survival of less than one year, with worse outcomes observed in those with advanced disease stage and hydronephrosis.